Cost-effectiveness of screening and treating anal pre-cancerous lesions among gay, bisexual and other men who have sex with men living with HIV
暂无分享,去创建一个
K. Howard | J. Ong | A. Newall | A. Grulich | G. Hruby | Qinglu Cheng | R. Hillman | F. Jin | D. Boettiger | I. Poynten
[1] J. Palefsky,et al. Treatment of Anal High-Grade Squamous Intraepithelial Lesions to Prevent Anal Cancer. , 2022, The New England journal of medicine.
[2] A. Devine,et al. Lifetime Cost of HIV Management in Australia: An Economic Model , 2021, Social Science Research Network.
[3] P. Tekkis,et al. Evaluating the efficacy of treatment options for anal intraepithelial neoplasia: a systematic review , 2020, International Journal of Colorectal Disease.
[4] E. Stier,et al. A meta‐analysis of anal cancer incidence by risk group: Toward a unified anal cancer risk scale , 2020, International journal of cancer.
[5] S. Garland,et al. The Natural History of Anal High-grade Squamous Intraepithelial Lesions in Gay and Bisexual Men. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[6] W. Quint,et al. Cancer Risk Stratification of Anal Intraepithelial Neoplasia in Human Immunodeficiency Virus–Positive Men by Validated Methylation Markers Associated With Progression to Cancer , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[7] F. Bray,et al. Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020-99: a modelling study. , 2019, The Lancet. Oncology.
[8] N. Paracha,et al. Systematic review of health state utility values in metastatic non-small cell lung cancer with a focus on previously treated patients , 2018, Health and Quality of Life Outcomes.
[9] J. Chhatwal,et al. Management of precancerous anal intraepithelial lesions in human immunodeficiency virus–positive men who have sex with men: Clinical effectiveness and cost‐effectiveness , 2017, Cancer.
[10] S. Franceschi,et al. Human papillomavirus types from infection to cancer in the anus, according to sex and HIV status: a systematic review and meta-analysis , 2017, The Lancet. Infectious diseases.
[11] S. Garland,et al. The performance of human papillomavirus biomarkers in predicting anal high-grade squamous intraepithelial lesions in gay and bisexual men , 2017, AIDS.
[12] S. Garland,et al. Prevalence and risk factors associated with high-grade anal squamous intraepithelial lesions (HSIL)-AIN2 and HSIL-AIN3 in homosexual men , 2016, Papillomavirus research.
[13] S. Vavricka,et al. Presenting symptoms predict local staging of anal cancer: a retrospective analysis of 86 patients , 2016, BMC Gastroenterology.
[14] J. Kaldor,et al. Cost-effectiveness of screening for anal cancer using regular digital ano-rectal examinations in men who have sex with men living with HIV , 2016, Journal of the International AIDS Society.
[15] A. Kneebone,et al. Implementing Intensity-modulated Radiotherapy with Simultaneous Integrated Boost for Anal Cancer: 3 Year Outcomes at Two Sydney Institutions. , 2015, Clinical oncology (Royal College of Radiologists (Great Britain)).
[16] Karen E Bremner,et al. A Review and Meta-analysis of Colorectal Cancer Utilities , 2014, Medical decision making : an international journal of the Society for Medical Decision Making.
[17] J. Debus,et al. Efficacy and toxicity of chemoradiation in patients with anal cancer - a retrospective analysis , 2014, Radiation oncology.
[18] S. Garland,et al. The Study of the Prevention of Anal Cancer (SPANC): design and methods of a three-year prospective cohort study , 2013, BMC Public Health.
[19] M. Dijkgraaf,et al. Comparison of imiquimod, topical fluorouracil, and electrocautery for the treatment of anal intraepithelial neoplasia in HIV-positive men who have sex with men: an open-label, randomised controlled trial. , 2013, The Lancet. Oncology.
[20] David P. Wilson,et al. Projected Demographic Profile of People Living with HIV in Australia: Planning for an Older Generation , 2012, PloS one.
[21] H. Jessen,et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. , 2011, The New England journal of medicine.
[22] C. Czoski-Murray,et al. Cost-effectiveness of screening high-risk HIV-positive men who have sex with men (MSM) and HIV-positive women for anal cancer. , 2010, Health technology assessment.
[23] J. Palefsky,et al. Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions , 2009, International journal of cancer.
[24] S. Franceschi,et al. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: A meta‐analysis , 2009, International journal of cancer.
[25] J. Karnon,et al. Cost-utility analysis of screening high-risk groups for anal cancer. , 2008, Journal of public health.
[26] J. Raftery. Paying for costly pharmaceuticals: regulation of new drugs in Australia, England and New Zealand , 2008, The Medical journal of Australia.
[27] J. Brazier,et al. The Estimation of a Preference-Based Measure of Health From the SF-12 , 2004, Medical care.
[28] J. Brazier,et al. The estimation of a preference-based measure of health from the SF-36. , 2002, Journal of health economics.
[29] C. Moore,et al. Rates of combination antiretroviral treatment change in Australia, 1997–2000 , 2002 .
[30] M. Weinstein,et al. The clinical effectiveness and cost-effectiveness of screening for anal squamous intraepithelial lesions in homosexual and bisexual HIV-positive men. , 1999, JAMA.
[31] C. Sherbourne,et al. The MOS 36-Item Short-Form Health Survey (SF-36) , 1992 .
[32] A. Harris,et al. Cost-Effectiveness Analysis and the Consistency of Decision Making , 2012, PharmacoEconomics.
[33] Australian Hiv Observational Database. Rates of combination antiretroviral treatment change in Australia, 1997-2000. , 2002, HIV medicine.
[34] A. Harris,et al. Cost-effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in australia (1991 to 1996). , 2001, PharmacoEconomics.
[35] Ware J.E.Jr.,et al. THE MOS 36- ITEM SHORT FORM HEALTH SURVEY (SF- 36) CONCEPTUAL FRAMEWORK AND ITEM SELECTION , 1992 .
[36] P. Feros. Pharmaceutical benefits scheme. , 1986, The Medical journal of Australia.